삼성서울병원

Ko En

Sun, Jong Mu M.D

TITLE
Clinical Associate Professor, Division of Hem/Oncology, Samsung Medical Center
Treament Schedule 08 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
SAT
29
SUN
30
MON
31
AM
PM
Treament Schedule 09 月
DATE
TUE
01
WEB
02
THU
03
FRI
04
SAT
05
SUN
06
MON
07
TUE
08
WEB
09
THU
10
FRI
11
SAT
12
SUN
13
MON
14
TUE
15
WEB
16
THU
17
FRI
18
SAT
19
SUN
20
MON
21
TUE
22
WEB
23
THU
24
FRI
25
SAT
26
SUN
27
MON
28
TUE
29
WEB
30
AM
PM

Medical School

School of Medicine, Seoul National University, Seoul, Korea

Specialty Training

Fellowship   Seoul National University Hospital
Samsung Medical Center
Residency   Seoul National University Hospital
Internship   Seoul National University Hospital

Clinical & Research Interests

Lung cancer, Head and neck cancer, breast cancer, gastric and colorectal cancer

Participation in Academic Societies
and Research

American Society of Clinical Oncology
International Association for the Study of Lung Cancer
Korean Association of Clinical Oncology
Koran Cancer Association

Selected Publications

  • LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2 Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study Ahn1, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32235 Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease Shin1, SH; Park, HY; Im, Y; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, HY; Lee, SH
    View PubMed
  • EUR J CANCER 2019 10.1016/j.ejca.2019.08.001 Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing Kim1, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-50574-6 Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab Eun1, Y; Kim, IY; Sun, JM; Lee, J; Cha, HS; Koh, EM; Kim, H; Lee, J
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014 DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC Park1, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K
    View PubMed